Across TCGA pan-cancer cohorts, C21orf62 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C21orf62 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher C21orf62 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C21orf62 expression acts as an unfavorable survival marker.

BLCA, CESC, and UCEC are the cancer types where C21orf62 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.051	0.600	<.001	12	view →
CESC	DFS	Median	All	0.467	0.742	.017	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C21orf62 tumor-vs-normal RNA expression · all C21orf62 data types